Tag: crizotinib

Better Practice: Improving first-line treatment against Stage 4 ALK-positive non-small cell lung cancer (NSCLC)

Introduction For patients with stage 4 lung adenocarcinoma, they should be tested for anaplastic lymphoma kinase (ALK) fusion oncogene rearrangements, which affects about 5% of non-small cell lung cancer (NSCLC). This group of stage 4 lung cancer is highly sensitive to ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, ensartinib and lorlatinib). Crizotinib The first ALK inhibitor … Continue reading Better Practice: Improving first-line treatment against Stage 4 ALK-positive non-small cell lung cancer (NSCLC)